Who Paid My Doc
A Phase 1, Single-Blind, Safety, Reactogenicity, and Immunogenicity Tr
Research payments
$1,482,385
Through program year 2024, $1,482,385 in research payments was reported against A Phase 1, Single-Blind, Safety, Reactogenicity, and Immunogenicity Tr, across 358 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $522 | 1 |
| 2023 | Research | $694,410 | 190 |
| 2022 | Research | $787,453 | 167 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
8 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Vicki Miller Tomball, TX Named on 74 payments
- James Andersen Lakeland, FL Named on 48 payments
- Valentine Ebuh Dallas, TX Named on 33 payments
- Barbara Rizzardi West Jordan, UT Named on 23 payments
- Jorge Caso Plantation, FL Named on 21 payments
- Eliyazar Gaddam Chicago, IL Named on 20 payments
- Beth Safirstein Hallandale Beach, FL Named on 15 payments
- Joan Rothenberg Beachwood, OH Named on 12 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.